Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Handheld Fan Direction for Breathlessness in Chronic Heart and Lung Disease

6. november 2026 oppdatert av: Mohamed Fakhry Ahmed Salem, Alexandria University

Fan-to-Face Versus Fan-to-Leg Versus No Fan on Exertional Breathlessness and Exercise Capacity With Stable Chronic Cardiopulmonary Disease: A Mixed Method Three-Arm Randomized Controlled Trial

People with chronic heart failure or chronic lung disease (such as COPD or interstitial lung disease) often feel short of breath when they exert themselves. A handheld fan blowing air on the face may ease this feeling, but it is not clear whether the benefit lasts with longer home use, whether it depends on the direction of the airflow, or whether it works in patients with heart disease and in hot climates.

This study will compare three conditions in adults with stable chronic heart and/or lung disease who become breathless on exertion: (1) a handheld fan directed at the face, (2) a handheld fan directed at the leg, and (3) no fan (usual care). Participants will be randomly assigned (1:1:1) to one of the three groups. The two fan groups will use the fan at home for 12 weeks. The no-fan group will receive a fan after the final assessment. The person measuring outcomes will not know which group each participant is in.

The main outcome is breathlessness (Borg 0-10 scale) in the 5 minutes after a 6-minute walk test at week 12. Other outcomes include walking distance, recovery time, breathlessness severity and impact (Dyspnoea-12), functional class, global change in breathlessness, fan use and acceptability, and emergency visits or hospital admissions.

The study also includes interviews with about 24 to 30 participants from the three groups after week 12, to understand how the fan was used, how acceptable it was, and how heat and humidity affected it. Trial and interview findings will be analysed separately and then combined.

Studieoversikt

Status

Har ikke rekruttert ennå

Forhold

Studietype

Intervensjonell

Registrering (Antatt)

129

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studiesteder

      • Alexandria, Egypt, 21511
        • Faculty of Nursing, Alexandria University

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • Adults with chronic heart failure and/or chronic lung disease (for example chronic obstructive pulmonary disease or interstitial lung disease) confirmed by a cardiologist or chest physician
  • Stable condition: heart failure NYHA class II to III, and no exacerbation of lung disease in recent weeks, confirmed with the treating specialist
  • Breathlessness on exertion, with an MRC dyspnoea grade and a Borg score after the 6-minute walk test at or above a minimum set in advance [FILL: e.g. Borg >= 3]
  • Stable medication, with no marked change in recent weeks [FILL: period set by the treating specialist]
  • Able to walk, answer the questionnaires and give written informed consent

Exclusion Criteria:

  • Acute heart failure, an acute exacerbation of lung disease, or a recent hospital admission
  • Another dominant cause of breathlessness (for example severe anemia, pulmonary embolism or neuromuscular disease)
  • Severe lung disease needing oxygen at rest
  • Unstable angina, recent myocardial infarction, or any condition that prevents walking or raises risk
  • Cognitive impairment that prevents responding, or inability to use the fan
  • Participation in another trial

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Støttende omsorg
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Enkelt

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Fan-to-Face

Handheld battery-operated fan directed at the face whenever the participant feels breathless, for 12 weeks at home. Participants receive training and a teach-back check at week 0 and keep a daily diary. Usual care continues unchanged.

Battery-operated handheld fan (same model and speed in both fan arms) directed at the face at a distance of about 15 to 30 cm whenever the participant feels breathless, for a set time per use after training. Used at home for 12 weeks.

Eksperimentell: Fan-to-Leg

Same handheld fan (same model and speed) directed at the leg at the same distance and for the same duration whenever the participant feels breathless, for 12 weeks at home. Training, teach-back, diary and usual care are the same as in the fan-to-face arm.

The same handheld fan directed at the leg at the same distance and for the same duration per use. Used at home for 12 weeks as an active comparator.

Ingen inngripen: No Fan

Usual care for the heart or lung disease for 12 weeks, with a daily diary of breathless episodes and the same visit and phone-call schedule. After the 6-minute walk test, participants rest seated for 5 minutes without a fan. A fan is offered after the week 12 assessment.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Breathlessness intensity (Borg CR10) after the 6-minute walk test
Tidsramme: Week 12

Breathlessness rated on the Borg CR10 scale (0 = nothing at all, 10 = maximal; higher is worse) during the 5 minutes of seated recovery after a 6-minute walk test, with a fan (fan-to-face and fan-to-leg arms) or seated rest without a fan (no-fan arm). Rated at minutes 1, 3 and 5; the minute used for the primary analysis is [FIX BEFORE SUBMITTING]. The walk test is done without a fan in all arms.

Week 12

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
6-minute walk distance
Tidsramme: Week 0 and week 12

Distance walked in 6 minutes.

Week 0 and week 12
Recovery time after exertion
Tidsramme: Week 0 and week 12

Minutes from the end of the walk test until Borg breathlessness first returns to the pre-test value, asked every minute for 5 minutes (censored at 5 minutes).

Week 0 and week 12
Borg CR10 breathing discomfort
Tidsramme: Week 0 and week 12

Borg CR10 rating of breathing discomfort (0 to 10, higher is worse), assessed before and at the end of the 6-minute walk test.

Week 0 and week 12
Dyspnoea-12 total score
Tidsramme: Week 0 and week 12

12 breathlessness descriptors, each scored 0 to 3; total 0 to 36 (higher is worse), with physical (0 to 21) and affective (0 to 15) components.

Week 0 and week 12
Functional class
Tidsramme: Week 0 and week 12

NYHA class (I to IV) in heart failure participants, and MRC dyspnoea grade (1 to 5) in all participants. Higher is worse.

Week 0 and week 12
Borg CR10 leg effort
Tidsramme: Time Frame: Week 0 and Week 12

Borg CR10 rating of leg effort (0 to 10, higher is worse), assessed before and at the end of the 6-minute walk test.

Time Frame: Week 0 and Week 12

Andre resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Qualitative experience, acceptability and context
Tidsramme: Within 7 days after the week 12 visit

Semi-structured interviews (30 to 45 minutes) with about 24 to 30 participants on how the fan was used, perceived mechanism, barriers, and effect of heat and humidity. Reflexive thematic analysis.

Within 7 days after the week 12 visit

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Etterforskere

  • Hovedetterforsker: Mohamed Fakhry Ahmed Salem, PHD, Alexandria University

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Antatt)

11. november 2026

Primær fullføring (Antatt)

3. februar 2027

Studiet fullført (Antatt)

10. februar 2027

Datoer for studieregistrering

Først innsendt

2. november 2026

Først innsendt som oppfylte QC-kriteriene

6. november 2026

Først lagt ut (Faktiske)

12. november 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

12. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

6. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Begreper knyttet til denne studien

Nøkkelord

Ytterligere relevante MeSH-vilkår

Andre studie-ID-numre

  • FANCP-2026-01

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere